Granzyme B PET/CT predicts chemo-immunotherapy outcomes in microsatellite stable gastric cancers.
2/5 보강
TL;DR
Subgroup analysis confirmed its reliable predictive power across neoadjuvant, palliative, and adjuvant treatments, supporting the potential for its broad clinical application.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
145 patients with MSS GC underwent [Ga]Ga-NOTA-GSI PET/CT after two or three cycles of chemo-immunotherapy.
I · Intervention 중재 / 시술
[Ga]Ga-NOTA-GSI PET/CT after two or three cycles of chemo-immunotherapy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] The study highlighted the significant value of [Ga]Ga-NOTA-GSI PET/CT in assessing the effectiveness of chemo-immunotherapy and predicting outcomes in MSS gastric cancer patients. Subgroup analysis confirmed its reliable predictive power across neoadjuvant, palliative, and adjuvant treatments, supporting the potential for its broad clinical application.
OpenAlex 토픽 ·
Gastric Cancer Management and Outcomes
Cancer Immunotherapy and Biomarkers
Esophageal Cancer Research and Treatment
Subgroup analysis confirmed its reliable predictive power across neoadjuvant, palliative, and adjuvant treatments, supporting the potential for its broad clinical application.
- p-value P < 0.05
- p-value P = 0.016
APA
Qiufang Liu, Ziyi Yang, et al. (2026). Granzyme B PET/CT predicts chemo-immunotherapy outcomes in microsatellite stable gastric cancers.. European journal of nuclear medicine and molecular imaging, 53(6), 3817-3826. https://doi.org/10.1007/s00259-025-07734-w
MLA
Qiufang Liu, et al.. "Granzyme B PET/CT predicts chemo-immunotherapy outcomes in microsatellite stable gastric cancers.." European journal of nuclear medicine and molecular imaging, vol. 53, no. 6, 2026, pp. 3817-3826.
PMID
41540242
Abstract
[BACKGROUND] Prognostic stratification for microsatellite stable (MSS) gastric cancer (GC) remains challenging. This study evaluated the predictive and prognostic value of [Ga]Ga-NOTA-GSI PET/CT imaging in a large cohort of MSS GC patients receiving chemo-immunotherapy.
[METHODS] In this retrospective study, 145 patients with MSS GC underwent [Ga]Ga-NOTA-GSI PET/CT after two or three cycles of chemo-immunotherapy. Measurements included SUVmax, SUVmean, GSI tumor volume (GSI-TV), total lesion uptake (TLU), tumor-liver ratio (TLR), and tumor-blood ratio (TBR). The study analyzed associations between short-term treatment response (RECIST 1.1 or tumor regression grade score) and progression-free survival (PFS) using receiver operating characteristic (ROC) curves, logistic regression, and Cox proportional hazards models.
[RESULTS] Responders exhibited significantly higher uptake of [Ga]Ga-NOTA-GSI than non-responders, including SUVmax, sumSUVmax, and TBR (all P < 0.05) across all patients and various subgroups, while volumetric parameters (GSI-TV, TLU) showed no notable difference. SUVmax was a reliable predictor of response (AUC = 0.755 for all patients; AUC = 0.882 for the neoadjuvant subgroup). In survival analysis, an SUVmax ≥ 2.6 independently predicted significantly longer PFS (median PFS of 14.0 vs. 9.0 months; hazard ratio, 0.673; P = 0.016).
[CONCLUSION] The study highlighted the significant value of [Ga]Ga-NOTA-GSI PET/CT in assessing the effectiveness of chemo-immunotherapy and predicting outcomes in MSS gastric cancer patients. Subgroup analysis confirmed its reliable predictive power across neoadjuvant, palliative, and adjuvant treatments, supporting the potential for its broad clinical application.
[METHODS] In this retrospective study, 145 patients with MSS GC underwent [Ga]Ga-NOTA-GSI PET/CT after two or three cycles of chemo-immunotherapy. Measurements included SUVmax, SUVmean, GSI tumor volume (GSI-TV), total lesion uptake (TLU), tumor-liver ratio (TLR), and tumor-blood ratio (TBR). The study analyzed associations between short-term treatment response (RECIST 1.1 or tumor regression grade score) and progression-free survival (PFS) using receiver operating characteristic (ROC) curves, logistic regression, and Cox proportional hazards models.
[RESULTS] Responders exhibited significantly higher uptake of [Ga]Ga-NOTA-GSI than non-responders, including SUVmax, sumSUVmax, and TBR (all P < 0.05) across all patients and various subgroups, while volumetric parameters (GSI-TV, TLU) showed no notable difference. SUVmax was a reliable predictor of response (AUC = 0.755 for all patients; AUC = 0.882 for the neoadjuvant subgroup). In survival analysis, an SUVmax ≥ 2.6 independently predicted significantly longer PFS (median PFS of 14.0 vs. 9.0 months; hazard ratio, 0.673; P = 0.016).
[CONCLUSION] The study highlighted the significant value of [Ga]Ga-NOTA-GSI PET/CT in assessing the effectiveness of chemo-immunotherapy and predicting outcomes in MSS gastric cancer patients. Subgroup analysis confirmed its reliable predictive power across neoadjuvant, palliative, and adjuvant treatments, supporting the potential for its broad clinical application.
MeSH Terms
Humans; Stomach Neoplasms; Male; Female; Positron Emission Tomography Computed Tomography; Middle Aged; Retrospective Studies; Aged; Treatment Outcome; Adult; Immunotherapy; Microsatellite Instability; Prognosis; Aged, 80 and over
같은 제1저자의 인용 많은 논문 (5)
- A Novel Preoperative Design to Address Dermatochalasis in Asian Upper Blepharoplasty.
- Sohlh2 inhibited the angiogenesis of hepatocellular carcinoma through the HIF-1α/VEGFA pathway.
- Integrated multi-omics, spatial profiling and organoid modeling drive transformative advances in chronic liver disease and hepatocellular carcinoma immunomicroenvironment research.
- Pharmacologic modulation of the SAT1-N1-acetylspermidine axis is associated with enhanced chemotherapy cytotoxicity in T-LBL/ALL cells.
- Integrative multi-omics and machine learning reveals the spatial niche distribution and role of CYP27A1TAMs in immunotherapy response in non-small cell lung cancer.